Reduction in sepsis mortality is directly dependent on early identification and rapid initiation of appropriate antimicrobial therapy. Fast and accurate diagnosis may also shorten the length of a hospital stay and potentially help reduce the emergence of multidrug-resistant bacteria.
During our September 12, 2019 webinar, titled, “New Technology and Workflow Optimization in the Microbiology Lab: Working Together to Improve Patient Care,” Dr. Allison McMullen, Ph.D., D(ABMM), will share how microbiology is meeting today’s clinical challenges in the context of Antimicrobial Stewardship Programs (ASPs).
The cornerstone of Cayuga Medical Center’s investment was the acquisition of a microbial identification technology using mass spectrometry, called MALDI-TOF mass spec. But Cayuga didn’t stop there.
By the bioMérieux Connection Editors In late 2013, the U.S. Food and Drug Administration (FDA) granted 510(k) de novo clearance to the first mass spectrometer for identifying disease-causing bacteria and yeast for clinical use in the U.S. market. The technology is called Matrix-Assisted Laser Desorption Ionization-Time of Flight mass spectrometry, or MALDI-TOF MS, and it uses a …